Annotation SNPEff_ Annotation SNPEff_. SNPEff_. Annotation. SNPEff_. Annotation. SNPEff_. Annotation. SNPEff_. Annotation
|
|
- Alexandrina Oliver
- 6 years ago
- Views:
Transcription
1 Chr Gene p-value Binned_ variants Phenotype Biological_Feature Note 11 DRD Asthma Gene 16 CES Asthma Gene 19 LDLR Asthma Gene 10 ARID5B Asthma Gene 10 CYP2C Asthma Gene 7 CYP3A Asthma Gene 5 DRD BPH Gene 11 BDNF BPH Gene 13 HTR2A Cataracts Gene 5 NR3C Cataracts Gene 10 CYP2C Cataracts Gene 1 DPYD Cataracts Gene 9 ABCA Cataracts Gene 1 CACNA1S Diverticulosis Gene 1 PEAR Diverticulosis Gene 5 HTR1A GERD Gene 10 ARID5B GERD Gene 16 HSD11B Hypertension Gene 7 GLCCI Hypertension Gene 17 CRHR Hypothyroidism Gene 1 DPYD Hypothyroidism Gene 16 VKORC Hypothyroidism Gene 14 TCL1A Hypothyroidism Gene 10 CYP2C Hypothyroidism Gene 6 ESR Hypothyroidism Gene 11 BDNF Type II Diabetes Gene 19 CYP2A Type II Diabetes Gene 11 SLCO2B Type II Diabetes Gene 15 CYP1A Type II Diabetes Gene 10 CYP2C Uterine Fibroids Gene 10 CYP2C Uterine Fibroids Gene 2 UGT1A Uterine Fibroids Gene 20 PTGIS Uterine Fibroids Gene 6 SLC22A Uterine Fibroids Gene 10 ABCC Uterine Fibroids Gene 13 HTR2A Uterine Fibroids Gene 5 HTR1A Uterine Fibroids Gene 12 SLCO1B Uterine Fibroids Gene 3 SCN5A Uterine Fibroids Gene 10 ARID5B ASTHMA 19 LDLR ASTHMA 4 NR3C ASTHMA 10 GRK ASTHMA 7 CYP3A ASTHMA 9 ABCA ASTHMA 2 ABCB ASTHMA PRIME_ DOWNSTREAM _
2 12 SLCO1A ASTHMA 16 CES ASTHMA 19 CYP2A ASTHMA 11 SLCO2B ASTHMA 7 POR ASTHMA 7 AHR ASTHMA 5 SLC6A ASTHMA 10 ALOX ASTHMA 11 DRD ASTHMA 22 CYP2D BPH 16 CES BPH 6 SLC22A BPH 4 GRK BPH 13 HTR2A Cataracts 10 CACNB Cataracts 20 PTGIS Cataracts 7 KCNH Cataracts 5 NR3C Cataracts 9 PTGS Cataracts 4 NR3C Cataracts 9 NTRK Cataracts 15 CYP1A Diverticulosis 14 TCL1A Diverticulosis 16 CES Diverticulosis 4 NR3C Diverticulosis 19 LDLR Diverticulosis 7 CYP3A Diverticulosis PRIME_ PRIME_ PRIME_ PRIME_
3 1 PEAR Diverticulosis 5 SLC6A Diverticulosis 7 AHR Diverticulosis 10 CYP2C Diverticulosis 7 TBXAS Diverticulosis 10 GRK Diverticulosis 1 CACNA1S Diverticulosis 16 CES Diverticulosis 12 CACNA1C GERD 10 ARID5B GERD 19 CYP2B GERD 7 GLCCI Hypertension 6 SLC22A Hypothyroidism 17 CRHR Hypothyroidism 1 DPYD Hypothyroidism 10 CYP2C Hypothyroidism 12 VDR Hypothyroidism 17 SLC47A Hypothyroidism 14 TCL1A Hypothyroidism 1 NPR Hypothyroidism 5 SLC6A Hypothyroidism 7 AHR Hypothyroidism 17 SLC47A Hypothyroidism 17 CRHR Hypothyroidism 6 ESR Hypothyroidism 7 TBXAS Hypothyroidism 9 ABCA Hypothyroidism PRIME_ PRIME_ PRIME_ PRIME_ PRIME_ PRIME_
4 22 COMT Hypothyroidism 16 CES Hypothyroidism 6 ESR Hypothyroidism 15 CYP1A Hypothyroidism 11 BDNF Type II Diabetes 16 ZNF Type II Diabetes 11 SLCO2B Type II Diabetes 11 SLCO2B Type II Diabetes 11 BDNF Type II Diabetes 12 CACNA1C Type II Diabetes 9 NTRK Type II Diabetes 17 SLC47A Type II Diabetes 15 CYP1A Type II Diabetes 6 SLC22A Type II Diabetes 5 NR3C Type II Diabetes 10 ALOX Type II Diabetes 19 CYP2A Type II Diabetes 20 PTGIS Type II Diabetes 6 SLC22A Type II Diabetes 10 CACNB Type II Diabetes 15 CYP1A Type II Diabetes 10 CYP2C Uterine Fibroids 2 UGT1A Uterine Fibroids 17 SLC47A Uterine Fibroids 9 DBH Uterine Fibroids 11 SLCO2B Uterine Fibroids 16 CES Uterine Fibroids PRIME_ PRIME_ SPLICE_SITE_ REGION_LOW PRIME_ PRIME_
5 3 SCN5A Uterine Fibroids 11 BDNF Uterine Fibroids 10 CYP2C Uterine Fibroids 7 TBXAS Uterine Fibroids 19 LDLR Uterine Fibroids 13 HTR2A Uterine Fibroids 5 NR3C Uterine Fibroids 12 CACNA1C Uterine Fibroids 11 DRD Uterine Fibroids X MAOA Uterine Fibroids 17 SLC47A Uterine Fibroids 6 SLC22A Uterine Fibroids PRIME_ PRIME_
New Advances in Psychiatric Genetics Joseph Shen, M.D., Ph.D. Aisha Furqan, LCGC Clinical Genetics UCSF-Fresno Community Regional Medical Center
New Advances in Psychiatric Genetics Joseph Shen, M.D., Ph.D. Aisha Furqan, LCGC Clinical Genetics UCSF-Fresno Community Regional Medical Center Background Genetic testing Treatment options: Pharmacogenetics
More informationGenomics & Personalized Medicine: Pharmacogenomics
Genomics & Personalized Medicine: Pharmacogenomics Russ B. Altman, MD, PhD Departments of Bioengineering & Genetics PharmGKB, http://www.pharmgkb.org/ Stanford University Outline of comments today Introduction
More informationDeliverable 2.1 List of relevant genetic variants for pre-emptive PGx testing
GA N 668353 H2020 Research and Innovation Deliverable 2.1 List of relevant genetic variants for pre-emptive PGx testing WP N and Title: WP2 - Towards shared European Guidelines for PGx Lead beneficiary:
More informationCardiovascular Health. Heart Disease / Atrial Fibrillation. Hypertension
P: 1300 688 522 E: info@nutripath.com.au A: PO Box 442 Ashburton VIC 3142 TEST PATIENT Sex : D Collected : 00-00-0000 111 ROAD TEST SUBURB AB : 00000000 UR#:0000000 TEST PHYSICIAN DR JOHN DOE 111 CLINIC
More informationGuidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Gene(s)/Level of evidence
Drug Gene(s)/Level of evidence Guidelines/Supporting Studies* FDA Label Information Additional Information/Commentsxc` Haloperidol CYP2D6 ( SLC6A5 ( 2D6: DPWG guidelines Reduce dose by 50% in PMs Aripiprazole
More informationGenomic Medicine for Physical and Mental Health
Genomic Medicine for Physical and Mental Health Transform your health and mood with DNA-directed healthcare Learn about your DNA and what makes you unique Have you been trying to lose weight and gain muscle
More informationCorporate Medical Policy
Corporate Medical Policy Genetic Testing for Mental Health Conditions File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_mental_health_conditions 1/2014 6/2017 6/2018
More informationPharmacogenomics Gene/Drug-Pair Decision Flow Charts 2017
Pharmacogenomics Gene/Drug-Pair Decision Flow Charts 2017 Atomoxetine Prescription CYP2D6 Genotype (AS = 0) (AS = 0.5 1.0) (As = 2.0) Ultrarapid (AS >2.0) Standard dose. Dose increase probably not necessary;
More informationWhat s New Medical Policy Updates October 2018
What s New Medical Policy Updates October 2018 Listed below are the recent changes made to policies within the Geisinger Health Plan Medical Policy Portfolio during the month of September that will become
More informationExons from 137 genes were targeted for hybrid selection and massively parallel sequencing.
SUPPLEMENTARY TABLES Supplementary Table 1. Targeted Genes ABL1 ABL2 AKT1 AKT2 AKT3 ALK APC ATM AURKA BCL2 BRAF BRCA1 BRCA2 CCND1 CCNE1 CDC73 CDH1 CDK4 CDK6 CDK8 CDKN1A CDKN2A CEBPA CHEK1 CHEK2 CREBBP
More informationGenetic Screening for ADR
Genetic Screening for ADR Mahidol University Faculty of Medicine Siriraj Hospital Manop Pithukpakorn, MD Division of Medical Genetics Department of Medicine concentration Drug level over time toxic optimum
More informationLMM / emerge III Network Reference Sequences October 2016 LMM / emerge III Network Consensus Actionable Gene List *ACMG56 gene
LMM / emerge III Network Consensus Actionable Gene List *ACMG56 gene ACTA2* Exon 02-09 NM_001613.2 DSG2* Exon 01-15 NM_001943.3 ACTC1* Exon 01-06 NM_005159.4 DSP* Exon 01-24 NM_004415.2 APC* Exon 01-15
More informationPrecision Medicine in Mental Health Care
Precision Medicine in Mental Health Care Study PI: David Oslin, MD 11/21/17 Background: Public Health Significance Depression is one of the world s great public health problems At least 1 in 7 Veterans
More informationGenetic Testing for Diagnosis and Management of Mental Health Conditions
Genetic Testing for Diagnosis and Management of Mental Health Conditions Policy Number: Original Effective Date: MM.02.026 07/01/2015 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration
More informationKailos Test Results Dr. Ronald McGlennen, Medical Director CLIA#: 01D
Kailos Test Results Dr. Ronald McGlennen, Medical Director ANTIEPILEPTICS Mephenytoin (MESANTOIN ) Phenytoin (DILANTIN ) Valproic Acid (DEPAKOTE, STAVZOR ) ANTIHYPERTENSIVES Atenolol (TENORMIN ) Enalapril
More informationAPPLICATIONS OF NEXT GENERATION SEQUENCING IN SOLID TUMORS - PATHOLOGIST PROSPECTIVE
AMP COMPANION MEETING SYMPOSIUM AT USCAP 2015 NEXT-GENERATION OF PATHOLOGY: ROLE OF PATHOLOGIST IN NGS-BASED PERSONALIZED MEDICINE APPLICATIONS OF NEXT GENERATION SEQUENCING IN SOLID TUMORS - PATHOLOGIST
More informationClinical Implementation of Pharmacogenetics Mary V. Relling, Pharm.D.
Clinical Implementation of Pharmacogenetics Mary V. Relling, Pharm.D. Actionable pharmacogenetic gene/drug pairs have been known for a long time Primaquine G6PD Codeine CYP2D6 Thiopurines TPMT 5FU DPYD
More informationPharmacogenomics In Psychiatry. Wolfgang Sadee OSU Program in Pharmacogenomics The Ohio State University. XGEN Group NIH PGRN
Pharmacogenomics In Psychiatry Wolfgang Sadee OSU Program in Pharmacogenomics The Ohio State University XGEN Group NIH PGRN Why do we need biomarkers in drug therapy? Limited efficacy Adverse drug effects
More informationPrecision Oncology: Experience at UW
Precision Oncology: Experience at UW Colin Pritchard MD, PhD University of Washington, Department of Lab Medicine WSMOS Meeting November 1, 2013 Conflict of Interest Disclosures I declare the following,
More informationTable of Contents. Preface Abstract Acknowledgements... 9
Table of Contents Preface... 5 Abstract... 7 Acknowledgements... 9 1. Introduction... 17 1.1 Bipolar Affective Disorder... 17 1.1.1 History and Symptomatology of Bipolar Disorder... 17 1.1.2 Pharmacotherapy...
More informationMedical Policy. MP Genetic Testing for Mental Health Conditions
Medical Policy MP 2.04.110 BCBSA Ref. Policy: 2.04.110 Last Review: 06/22/2017 Effective Date: 06/22/2017 Section: Medicine End Date: 06/26/2018 Related Policies 2.04.38 Cytochrome p450 Genotyping 2.04.82
More informationThe Gene Connection: Integrating Genetic Variant Data into Treatment Planning
The Gene Connection: Integrating Genetic Variant Data into Treatment Planning Daniel Emina M.D. Child, Adolescent and Adult Psychiatrist Amen Clinics Walnut Creek, CA Introduction My people perish from
More informationWhole Exome Sequencing (WES): Questions and Answers for Providers
Whole Exome Sequencing (WES): Questions and Answers for Providers 1. What is Whole Exome Sequencing?... 2 2. What is the difference between Whole Exome Sequencing (WES) and Whole Exome Sequencing Plus
More informationR.G.C.C.- RESEARCH GENETIC CANCER CENTRE LTD
R.G.C.C.- RESEARCH GENETIC CANCER CENTRE LTD Florina, / /2015 Dear Colleague, We report the allelic discrimination results for patient Mr/ Ms whose sample receipt on / /2015. DNA was extracted from blood
More information3. Describe how variants in the CYP2C19 gene impact Plavix metabolism. 4. Compare molecular genetic technologies for pharmacogenomics testing
UP! UNDERSTANDING PHARMACOGENOMICS (PGX) Robert Pyatt Ph.D., Director Sanford Medical Genetics and Genomics Laboratories and Associate Professor, Dept of Internal Medicine, University of South Dakota April
More informationdevseek (Sequence(Analysis(Panel(for(Neurodevelopmental(Disorders
ACSL4 Mental/retardation,/XBlinked/63 XLBR ADSL Adenylosuccinase/Deficiency AR AFF2 Mental/retardation,/XBlinked,/FRAXE/type XLBR ALG6 Congenital/disorder/of/glycosylation/type/Ic AR ANK3 Mental/retardation,/autosomal/recessive/37
More informationPERSONAL GENOMICS TEST. Saved by Personal Genomics test. Now I can manage my Diabetes better
PERSONAL GENOMICS TEST My mother had Cancer but i need not worry about it Saved by Personal Genomics test An early diagnosis saved me from surgery Avoided Heart Attack INDIA s # 1 PERSONAL GENOMICS TEST
More informationCognitive and Behavioral Phenotypes: SNPs of Interest
Cognitive and Behavioral Phenotypes: SNPs of Interest Chr Apolipoprotein E (APOE) 19 Trait Associated with the Alzheimer s Disease, Cognitive Function SNP Position 1,2,5,6,7, 11,20,23, 24,30,34,35 coded_a
More informationPharmacokinetic-guided Antiretroviral Therapy. Chih-Hsun Tai, M.S., RPh. Department of Pharmacy National Taiwan University Hospital
Pharmacokinetic-guided Antiretroviral Therapy Chih-Hsun Tai, M.S., RPh. Department of Pharmacy National Taiwan University Hospital Introduction HAART allows a complete viral suppression But Not all patients
More informationNovel Methods to Identify Pain Targets : Genomic/Genetic Approaches
Novel Methods to Identify Pain Targets : Genomic/Genetic Approaches Luda Diatchenko, MD, PhD Canada Excellence Research Chair in Human Pain Genetics Alan Edwards Centre for Research on Pain, McGill University,
More informationWhite Paper. The Genes Analyzed by the Genecept Assay. May dynacare.ca
White Paper The Genes Analyzed by the Genecept Assay May 2017 888.988.1888 DynacareNext@dynacare.ca dynacare.ca GEN-WP003-v5-052017 INTRODUCTION Dynacare is pleased to present this summary of the genes
More informationSAMPLE REPORT MENTAL HEALTH DNA INSIGHT LABORATORY INFO. Protected Health Information. SSRIs. TCAs. Other Antidepressants
Test Results Reviewed & Approved by: Laboratory Director, Nilesh Dharajiya,.D. ENTAL HEALTH DNA INSIGHT PERSONAL DETAILS DOB Jan 1, 19XX ETHNICITY Caucasian ORDERING HEALTHCARE PROFESSIONAL Glenn Braunstein.D.
More informationWhite Paper. The Science Behind the Genecept Assay. January, 2016
White Paper The Science Behind the Genecept Assay January, 2016 Genomind, Inc. 2200 Renaissance Blvd Suite 100 King of Prussia, PA 19406 877.895.8658 www.genomind.com GEN WP003 v3 01182016 INTRODUCTION
More informationChanging the Culture of Cancer Care II. Eric Holland Fred Hutchinson Cancer Research Center University of Washington Seattle
Changing the Culture of Cancer Care II Eric Holland Fred Hutchinson Cancer Research Center University of Washington Seattle Transforming Cancer Therapy Eric Holland Fred Hutchinson Cancer Research Center
More informationCPT Codes for Pharmacogenomic Tests
CPT s for Pharmacogenomic Tests The table below lists CPT codes and lab fee information for pharmacogenomic tests as established by the Centers for Medicare and Medicaid Services. It was compiled by the
More informationComprehensive PGx report for John Doe. Current Patient Medication
Comprehensive PG report for John Doe Patient: Accession #: Collection Date: Order By: DOB: Gender: Received Date: Report Generated: Current Patient Medication Aspirin: A labile ester, is rapidly hydrolyzed--primarily
More informationGenetic Testing for Diagnosis and Management of Behavioral Health Conditions
Medical Policy Manual Genetic Testing, Policy No. 53 Genetic Testing for Diagnosis and Management of Behavioral Health Conditions Next Review: February 2019 Last Review: September 2018 Effective: October
More informationVariability Due to Genetic Differences
1 Variability Due to Genetic Differences Nick Holford Dept Pharmacology & Clinical Pharmacology University of Auckland 2 Objectives Understand how between individual variation may contribute to :» drug
More informationImipramine therapy (CYP2D6)
Imipramine therapy (CYP2D6) Intake Start therapy 1st conc 08:00 2nd conc 3e spiegel 4e spiegel 1 week 1 week 1 week 1 week 1 week 22:00 ~ 50% patients need dose adjustment Imipramine therapy (CYP2D6) Intake
More informationCORE DME PANEL Highlands Parkway, Suite 100 Smyrna, GA 30082
CORE DME PANEL Castle's CORE DME panel predicts the activity levels of key - drug metabolizing enzymes in the cytochrome P450 superfamily: CYP2D6, CYP2C9, CYP2C19, CYP2B6, CYP3A4, and - CYP3A5. Apart from
More informationComprehensive Drug Information for Smith, John
PATIENT INFORMATION Name: Smith, John DOB: April 22, 1973 Age: 42 Sex: Male SAMPLE Date Collected: March 21, 2016 Date Received: March 21, 2016 Case ID: CARDI16-000001 Source: Buccal Swabs Comprehensive
More informationPersonalized Prescribing: Using Genetic Testing to Guide Drug and Dose Selection. Lindsay S. Elliott, Pharm.D., CGP
Personalized Prescribing: Using Genetic Testing to Guide Drug and Dose Selection Lindsay S. Elliott, Pharm.D., CGP Disclosure I, Lindsay Elliott, am a pharmacy consultant for Genelex Corporation in conducting
More informationPsychiatric Pharmacogenomics: Introduction and Applications
Psychiatric Pharmacogenomics: Introduction and Applications Moises Gaviria, MD Distinguished Professor of Psychiatry University of Illinois at Chicago Medical Director The Institute of Neurobehavioral
More informationLiterature Summary Genecept Assay 2.0
Literature Summary Genecept Assay 2.0 March 2017 The following is a summary of the key published literature relevant to a variety of genetic variations. The purpose of this document is to summarize the
More informationColin Ross, PhD Centre for Molecular Medicine & Therapeutics Department of Medical Genetics University of British Columbia
Introduction to Pharmacogenomics for Clinicians: Pharmacogenomics of Adverse Drug Reactions Colin Ross, PhD Centre for Molecular Medicine & Therapeutics Department of Medical Genetics University of British
More informationPharmacogenomics-based individualization of drug therapy
ETH Zurich-JST Workshop on Medical Research, 15 Sep 2008 Pharmacogenomics-based individualization of drug therapy Taisei Mushiroda, Ph.D. Laboratory for Pharmacogenetics Center for Genomic Medicine, RIKEN
More informationOligo GEArray DNA Microarray:
Oligo GEArray DNA Microarray: Rat Toxicology and Drug Resistance Catalog Number ORN-401 ERN-401 Format: HybTube (Standard protocol) HybPlate (Higher throughput protocol) Description The Oligo GEArray Rat
More informationPractical implementation of personalized nutrition goals
Practical implementation of personalized nutrition goals We all have our own nutritional needs because we are different in so many ways. Gender, age, body size, physical activity, genomic variation, gut
More informationNetwork Characteristic Analysis of ADR-related Proteins and. Identification of ADR-ADR Associations. Supplementary Material List
Network Characteristic Analysis of ADR-related Proteins and Identification of ADR-ADR Associations Xiujie Chen*, Xiangqiong Liu, Xiaodong Jia, Fujian Tan, Ruizhi Yang, Sheng Chen, Lei Liu, Yunfeng Wang,
More informationPharmacogenetics in: Primary Care. Bradley T. Wajda D.O.
Pharmacogenetics in: Primary Care Bradley T. Wajda D.O. Pharmacogenomics Defined Pharmacogenomics uses information about a person s genetic makeup, or genome, to choose the drugs and drug doses that are
More informationShashikant Kulkarni, M.S (Medicine)., Ph.D., FACMG Associate Professor of Pathology & Immunology Associate Professor of Pediatrics and Genetics
Shashikant Kulkarni, M.S (Medicine)., Ph.D., FACMG Associate Professor of Pathology & Immunology Associate Professor of Pediatrics and Genetics Director of Cytogenomics and Molecular Pathology Evidence-based
More informationPharmacogenomics in the treatment of mood disorders: Strategies and Opportunities for personalized psychiatry
EPMA Journal (2017) 8:211 227 DOI 10.1007/s13167-017-0112-8 REVIEW Pharmacogenomics in the treatment of mood disorders: Strategies and Opportunities for personalized psychiatry Azmeraw T. Amare 1 & Klaus
More informationPharmacogenetics: LabQuality Days Helsinki, February 8, Do you have your DNA passport? Prof Dr Ron van Schaik
LabQuality Days Helsinki, February 8, 2018 Pharmacogenetics: Do you have your DNA passport? Prof Dr Ron van Schaik International Expert Center Pharmacogenetics Dept Clinical Chemistry - Erasmus MC Rotterdam,
More informationTBBPA. 31 August 2014 Green Science Policy Madrid, Spain. National Institutes of Health U.S. Department of Health and Human Services
TBBPA Linda S. Birnbaum, Ph.D., D.A.B.T., A.T.S. Director, National Institute of Environmental Health Sciences and National Toxicology Program Principle Investigator, National Cancer Institute 31 August
More informationYes if indicated below. (4.0 TMPT does not require prior authorization)
Genetic Testing for Pharmacogenetics MP9479 Covered Service: Prior Authorization Required: Additional Information: Medicare Policy: BadgerCare Plus Policy: Yes when meets criteria below Yes if indicated
More informationGenetics and pharmacogenetics of mood disorders
Psychiatr. Pol. 2017; 51(2): 197 203 PL ISSN 0033-2674 (PRINT), ISSN 2391-5854 (ONLINE) www.psychiatriapolska.pl DOI: https://doi.org/10.12740/pp/68914 Genetics and pharmacogenetics of mood disorders Alessandro
More informationSupplementary Table 1. Candidate loci that were associated with diabetes- and/or obesity-related traits.
Supplementary Table 1. Candidate loci that were associated with diabetes- and/or obesity-related traits. All With Fst in the With long With SNP(s) at the 5' top 5% bracket haplotypes regulatory region
More informationBiological and Experimental Psychology School of Biological and Chemical Sciences Individual Differences in Environmental Sensitivity
Biological and Experimental Psychology School of Biological and Chemical Sciences Individual Differences in Environmental Sensitivity Michael Pluess, PhD CYFS Signature Event Series, University of Nebraska-Lincoln
More informationNutraHacker. Complete Gene Mutation Report for Customer: 4c72ce3a-1fff-4f58-981c-b4946d512e3b. Instructions:
NutraHacker Complete Gene Mutation Report for Customer: 4c72ce3a-1fff-4f58-981c-b4946d512e3b Instructions: NutraHacker reports mutations (single nucleotide polymorphisms) in this uploaded genome. Genes
More informationNutraHacker. Carrier and Drug Response Report for Customer: b2b0b618-db91-447c-9470-ff7b79ae147d. Instructions:
NutraHacker Carrier and Drug Response Report for Customer: b2b0b618-db91-447c-9470-ff7b79ae147d Instructions: In this report, NutraHacker examines single nucleotide polymorphisms that reveal carrier status
More informationOmics Approaches based on Multi-Organ Interaction and Screening the Predictive Biomarkers
Omics Approaches based on Multi-Organ Interaction and Screening the Predictive Biomarkers May 18, 2017 Jung-Hwa Oh Department of Predictive Toxicology Korea Institute of Toxicology R&D for Predictive Toxicology
More informationMental Health DNA Insight WHITE PAPER
Mental Health DNA Insight WHITE PAPER JULY 2016 Mental Health DNA Insight / White Paper Mental Health DNA Insight Pathway Genomics Mental Health DNA Insight test is aimed to help psychiatrists, neurologists,
More informationFEP Medical Policy Manual
FEP Medical Policy Manual Last Review: December 2016 Effective Date: January 15, 2017 Related Policies: 2.04.38 Cytochrome P450 Genotyping 2.04.92 General Approach to Evaluating the Utility of Genetic
More informationLinking Pharmacovigilance and Pharmacogenomics
Linking Pharmacovigilance and Pharmacogenomics Dr. Bruce Carleton Professor of Pediatrics, Pharmaceutical Sciences, Population & Public Health, Medical Genetics, University of British Columbia Director,
More informationThe importance of pharmacogenetics in the treatment of epilepsy
The importance of pharmacogenetics in the treatment of epilepsy Öner Süzer and Esat Eşkazan İstanbul University, Cerrahpaşa Faculty of Medicine, Department of Pharmacology and Clinical Pharmacology Introduction
More informationCore Data Set CYP2D6 Metabolism
Core Data Set CYP2D6 Metabolism Oxidised metabolites seen in pre-clinical species Inhibitor Target CYP Isoform CLint (µl/min/mg protein) % Inhibition Control 12.5 - Furafylline 1A2 12.9 0 Sulfaphenoxazole
More informationSimilarities and Differences in the Expression of Drug-Metabolizing Enzymes between Human Hepatic Cell Lines and Primary Human Hepatocytes S
Supplemental material to this article can be found at: http://dmd.aspetjournals.org/content/suppl/2010/12/13/dmd.110.035873.dc1 0090-9556/11/3903-528 538 DRUG METABOLISM AND DISPOSITION Vol. 39, No. 3
More informationDetox Genomics. Client Name:
Detox Genomics Client Name: Phase 1 Detoxification TIC DA CYP1A1 CYP1B1(1) CYP1B1(2) CYP2A6 CYP2A6(2) CYP2C9 CYP2C19 CYP2D6 CYP2D6(2) CYP2D6(3) CYP2E1(1) CYP2E1(2) CYP3A4 AT Phase I detoxification is handled
More informationGENETICS NOMENCLATURE UPDATE
Medical Policy MP 2.04.131 BCBSA Ref. Policy: 2.04.131 Last Review: 06/27/2018 Effective Date: 06/27/2018 Section: Medicine Related Policies 2.04.38 Cytochrome p450 Testing 2.04.110 Genetic Testing for
More informationAncillary risk information and pharmacogenetic tests: social and policy implications
(2008) 8, 85 89 & 2008 Nature Publishing Group All rights reserved 1470-269X/08 $30.00 www.nature.com/tpj [Ethical Economic Legal & Social] EELS PAPER Ancillary risk information and pharmacogenetic tests:
More informationHow to use pharmacogenetics to select patients for pharmaceutical care
How to use pharmacogenetics to select patients for pharmaceutical care Prof. Henk-Jan Guchelaar Dept. of Clinical Pharmacy & Toxicology Leiden University Medical Center University of Leiden PCNE Working
More informationPharmacogenetic Testing for Pain Management
Pharmacogenetic Testing for Pain Management Policy Number: 2.04.131 Last Review: 8/2018 Origination: 8/2015 Next Review: 8/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will not provide
More informationGenetic factors in hypospadias
Genetic factors in hypospadias Loes FM van der Zanden Radboud university medical center, Nijmegen, Netherlands Department for Health Evidence, Loes.vanderZanden@radboudumc.nl AGORA project Aetiologic research
More informationPharmacokinetics, pharmacodynamics and pharmacogenetics of aripiprazole and olanzapine in healthy subjects
Pharmacokinetics, pharmacodynamics and pharmacogenetics of aripiprazole and olanzapine in healthy subjects Dr. Francisco Abad Santos 16 June 2017 Atypical antipsychotics or second generation antipsychotics
More informationUsing Genetics for Personal Nutritional Guidance Martin Kohlmeier, MD, PhD
Using Genetics for Personal Nutritional Guidance Martin Kohlmeier, MD, PhD University of North Carolina at Chapel Hill Department of Nutrition and UNC Nutrition Research Institute mkohlmeier@unc.edu Disclosures
More informationCurrent Patient Medications
Current Patient Medications Sertraline, Levothyroxine, Simvastatin, Amitriptyline Amitriptyline Increased Sensitivity to Amitriptyline (CYP2C19: Rapid Metabolizer) Consider an alternative drug, or consider
More informationPharmacogenetic and Genomic Approaches to Drug-Transporter Interactions. Wolfgang Sadee Program in Pharmacogenomics
Pharmacogenetic and Genomic Approaches to Drug-Transporter Interactions Wolfgang Sadee Program in Pharmacogenomics Molecular Functions of 26,383 Proteins Venter et al. Science 291:1335, 2001 SLC and ABC
More informationSupplemental Table 1: List of genes contained on the custom Steroltalk v2 microarray prepared for this study
Supplemental Table 1: List of genes contained on the custom Steroltalk v2 microarray prepared for this study Gene GenBank No. Description Ch25h NM_009890 Cholesterol 25-hydroxylase Bile acid synthesis
More informationThe Promise of Epilepsy Genetics A Personal & Scientific Perspective December 3, 2012
The Promise of Epilepsy Genetics A Personal & Scientific Perspective December 3, 2012 Tracy Dixon-Salazar, Ph.D. University of California, San Diego American Epilepsy Society Annual Meeting 1 Disclosure
More informationGenetic Testing for Pharmacogenetics
Genetic Testing for Pharmacogenetics MP9479 Covered Service: Yes when meets criteria below Prior Authorization Required: Yes-as shown below (1.0 and 3.0) Additional Information: None Prevea360 Health Plan
More informationNutraHacker. Complete Gene Mutation Report for Customer: 1428d57e bc-8bfa-fa3c85dda19b. Instructions:
NutraHacker Complete Gene Mutation Report for Customer: 1428d57e-7796-40bc-8bfa-fa3c85dda19b Instructions: NutraHacker reports mutations (single nucleotide polymorphisms) in this uploaded genome. Genes
More informationProtocol. Genetic Testing for Mental Health Conditions
Protocol Genetic Testing for Mental Health Conditions (204110) Medical Benefit Effective Date: 04/01/16 Next Review Date: 01/19 Preauthorization Yes Review Dates: 07/14, 01/15, 01/16, 01/17, 01/18 Preauthorization
More informationTitle: Candidate Gene Association Studies of Anthracycline-induced Cardiotoxicity: A
1 Title Page Title: Candidate Association Studies of Anthracycline-induced Cardiotoxicity: A Systematic Review and Meta-analysis. Authors: Siew Lian Leong 1,2, Nathorn Chaiyakunapruk 1,3,4,5, Shaun Wen
More informationTable 1 Functional polymorphisms identified by XGEN group, Center for Pharmacogenomics in OSU College of Medicine.
Table 1 Functional polymorphisms identified by XGEN group, Center for Pharmacogenomics in OSU College of Medicine. Gene Functional polymorphisms or haplotypes identified Functions of polymorphisms or haplotypes
More informationGene Expression Multiplexing Menu
Gene Expression Multiplexing Menu Mouse Rat Human Table of CONTENTS Mouse Inflammatory Plex 2 Rat Stress Plex 3 Growth Regulation Plex 4 Multitox Plex 5 Pharma III Plex 6 Reference Plex 7 Human Transporter
More informationTable of Contents I. ICD-10 Diagnosis Code Driven Result II. Current Medication List Clinical interpretation for patient s current medications provide
PATIENT INFORMATION Name: Smith, John DOB: October 9, 197 Age: Sex: Male Address: 16 Corporate Blvd. South Plainfield, NJ 07080 SAMPLE REPORT SAMPLE Date Collected: December 7, 017 Date Received: December
More informationGenetic Testing for Mental Health Conditions
Genetic Testing for Mental Health Conditions Policy Number: Original Effective Date: MM.02.026 07/01/2015 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 07/01/2015 Section: Medicine
More informationMyriad Genetics Corporate Presentation 06/13/2018
Myriad Genetics Corporate Presentation 06/13/2018 Copyright 2016 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com. 1 Forward Looking Statements Some of the information presented here today
More informationDynamic DNA Laboratories, LLC - DO NOT DISTRIBUTE
Cardiovascular Pharmacogenetic Report Created for: Patty Pain Patient: Patty Pain DOB: 1/1/1970 Accession #: 988889 SSN: Collection Date: Received Date: Ordering Physician: Report Generated: 1/28/2016
More informationDeriving Rules and Assertions From Pharmacogenomic Knowledge Resources In Support Of Patient Drug Metabolism Efficacy Predictions!
Deriving Rules and Assertions From Pharmacogenomic Knowledge Resources In Support Of Patient Drug Metabolism Efficacy Predictions! Casey L. Overby 1,2, Beth Devine 1, Peter Tarczy-Hornoch 1, Ira Kalet
More informationSAMPLE REPORT MENTAL HEALTH DNA INSIGHT
PERSONAL DETAILS DOB Jan 1, 19XX ETHNICITY Caucasian ORDERING HEALTHCARE PROFESSIONAL Glenn Braunstein.D. 6777 Nancy Ridge Drive San Diego, CA 92121 US LABORATORY INFO ACCESSION NUBER ACTIVATION CODE SPECIEN
More informationObjectives. Clinical Problem. What if there were a way. Pharmacogenomics in Current Practice MEDICINE 12/1/2017
Objectives Pharmacogenomics in Current Practice Trinh Pham, PharmD, BCOP Associate Clinical Professor University of Connecticut School of Pharmacy Review the concept of pharmacogenetics and pharmacogenomics
More informationGenes and environment: The complex etiology of psychiatric disorders
Genes and environment: The complex etiology of psychiatric disorders János Réthelyi, M.D., Ph.D. Department of Psychiatry and Psychotherapy Semmelweis University September 18th 2013 Outline The issue of
More informationReview of Pharmacogenetic Testing Today
Review of Pharmacogenetic Testing Today Gwen McMillin, PhD ARUP Laboratories University of Utah Salt Lake City, Utah A customer says to the pharmacist: "Why does my medication have 40 side effects?" The
More informationProgress towards an individualized approach to therapy: colorectal cancer
Progress towards an individualized approach to therapy: colorectal cancer Alan P. Venook, M.D. University of California, SF GIST: PET change after 4 weeks imatinib Multiple liver and upper abdominal 18
More informationGenetic and biochemical characteristics of patients with hyperlipidemia who require LDL apheresis
Genetic and biochemical characteristics of patients with hyperlipidemia who require LDL apheresis Mato Nagel, Ioan Duma, Constantina Vlad, Mandy Benke, Sylvia Nagorka Zentrum für Nephrologie & Stoffwechsel,
More informationPharmacogenomics in Current Practice. Trinh Pham, PharmD, BCOP Associate Clinical Professor University of Connecticut School of Pharmacy.
Pharmacogenomics in Current Practice Trinh Pham, PharmD, BCOP Associate Clinical Professor University of Connecticut School of Pharmacy Objectives Review the concept of pharmacogenetics and pharmacogenomics
More informationaccesalabs.c
Patient: DOB: Sex: F MRN: JANE DOE (CYP1A1) detoxifies polycyclic aromatic hydrocarbons (PAHs) produced from the combustion of organic materials (exhaust fumes, charbroiled meats, etc.). (CYP1B1) is involved
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): October 1, 2014 Most Recent Review Date (Revised): May 20, 2014 Effective Date: October 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT
More information